13F Holdings
中文EN

CRDF Cardiff Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213037 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.6%
TTM net income YoY25.3%
TTM EPS YoY31.6%
Revenue 3-yr CAGR6.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-7,068.2%
Net margin-6,735.2%
FCF margin—
EBITDA margin-7,005.5%

Returns

ROE-97.9%
ROA-75.2%
ROIC (approx.)-114.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets22.8%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.06x
Accruals ratio4.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$593,000$683,000$488,000$386,000$359,000
R&D expense$35.33M$36.85M$32.86M$27.11M$17.38M
SG&A expense$14.22M$12.48M$13.04M$13.18M$11.84M
Operating income-$48.96M-$48.65M-$45.41M-$39.90M-$28.86M
Interest expense————$0
Pretax income-$45.85M-$45.43M———
Income tax$0$0$0$0$0
Net income-$45.85M-$45.43M-$41.44M-$38.70M-$28.29M
EBITDA-$48.60M-$48.25M-$45.01M-$39.67M-$28.40M
EPS (basic)-0.69-0.95-0.93-0.89-0.73
EPS (diluted)-0.69-0.95-0.93-0.89-0.73
Weighted avg. shares (diluted)66.84M47.65M44.68M43.60M39.03M
Balance sheet
Cash & equivalents$17.47M$51.47M$21.66M$16.35M$11.94M
Short-term investments$40.83M$40.28M$53.17M$88.92M$128.88M
Receivables$182,000$773,000$288,000$771,000$535,000
Current assets$60.13M$95.05M$77.41M$111.28M$146.13M
PP&E, net$578,000$898,000$1.24M$1.27M$382,000
Total assets$61.88M$97.19M$81.64M$116.19M$149.54M
Current liabilities$16.39M$13.43M$10.44M$7.81M$6.56M
Total liabilities$16.50M$14.24M$11.90M$9.85M$9.13M
Shareholders' equity$45.39M$82.95M$69.74M$106.34M$140.42M
Shares outstanding68.31M66.52M44.68M44.68M41.96M
Cash flow statement
Operating cash flow-$37.92M-$37.69M-$30.89M-$33.82M-$23.04M
Capital expenditure$44,000$80,000$582,000$1.01M$205,000
Free cash flow-$37.97M-$37.77M-$31.47M-$34.83M-$23.25M
Investing cash flow$1.34M$13.73M$36.20M$38.15M-$131.45M
Financing cash flow$2.58M$53.78M$0$75,000$35.45M
Depreciation & amortization$364,000$404,000$398,000$236,000$451,000
Stock-based compensation$5.69M$4.76M$4.51M$4.26M$3.23M

Free plan shows the latest 5 periods; Pro shows all 25 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.